CRISPR Therapeutics AG
NASDAQ:CRSPBiotechnology
+$1.43 today
- Market cap
- $3.90B
- Beta
- 1.70
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$5.92
Volume 3.97M
Average 1.70M
CRSP Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
CRISPR Therapeutics AGNASDAQ: CRSP
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents falls 33.8% from a year ago
Cash & equivalents stood at $192.03M at the end of Q3 FY2026, down 33.8% from a year earlier and down 34.1% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.
Context
- Cash & equivalents amounted to 7.5% of total assets at the end of Q3 FY2026, down 5.4 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -33.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 355.19M USD
- Year-over-year change
- +19.1%
- 4-year CAGR
- -21.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 355.19M | +19.1% |
| FY2024 | 2024-12-31 | 298.26M | -23.4% |
| FY2023 | 2023-12-31 | 389.48M | +83.8% |
| FY2022 | 2022-12-31 | 211.89M | -77.0% |
| FY2021 | 2021-12-31 | 923.03M | — |
Cash & Equivalents vs competitors
How CRSP compares with its peers on the latest reported figures
- CRSP's Sep 2026 cash & equivalents of $192.03M is the 2nd highest of the 7 companies compared; the peer median is $129.17M.
- Its year-over-year change of -33.8% is the 5th highest of 7, against a peer median of -16.5%.
- Cash & equivalents amounts to 7.5% of total assets for CRSP, versus a peer median of 16.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $219.83M | -22.1% | +8.2% | 15.9% | |
| Sep 2026 | $192.03M | -33.8% | +18.8% | 7.5% | |
| Mar 2026 | $143.86M | -54.0% | -49.7% | 13.9% | |
| Mar 2026 | $134.7M | +6.2% | -33.3% | 17.8% | |
| Mar 2026 | $123.65M | -10.8% | +1.2% | 82.8% | |
| Mar 2026 | $99.37M | +28.7% | -16.4% | 69.1% | |
| Mar 2026 | $15.23M | -88.3% | -29.2% | 4.5% | |
| Peer median (excluding CRSP) | $129.17M | -16.5% | -22.8% | 16.8% | |
Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 923.03M | 211.89M | 389.48M | 298.26M | 355.19M |
| Short-term Investments | 1.46B | 1.6B | 1.3B | 1.61B | 1.63B |
| Net Receivables | 305K | 0 | 200M | 25M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.4M | 11.7M | 6.5M | 8.31M | 9.84M |
| Total Current Assets | 2.42B | 1.85B | 1.91B | 1.94B | 1.99B |
| Property, Plant & Equipment (Net) | 312.04M | 320.56M | 305.94M | 277.55M | 247.58M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 125K | 71K | 16K | 0 | 0 |
| Long-term Investments | 0 | 53.13M | 1.97M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 22.2M | 16.28M | 13.57M | 27.35M | 32M |
| Total Non-current Assets | 334.36M | 390.03M | 321.49M | 304.9M | 279.57M |
| Total Assets | 2.75B | 2.24B | 2.23B | 2.24B | 2.27B |
| Account Payables | 14.82M | 27.43M | 38.15M | 14.71M | 11.14M |
| Short-term Debt | 12.16M | 15.84M | 15.63M | 17.29M | 18.58M |
| Tax Payables | 0 | 0 | 0 | 451K | 0 |
| Deferred Revenue | 1.01M | 0 | 4.11M | 3.85M | 15.77M |
| Other Current Liabilities | 67.51M | 58.46M | 33.13M | 33.05M | 89.55M |
| Total Current Liabilities | 119.88M | 121.11M | 108.79M | 87.78M | 149.12M |
| Long-term Debt | 0 | 0 | 0 | 0 | 188.17M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 12.32M | 12.32M | 14.01M | 12.32M | 0 |
| Other Non-current Liabilities | 7.34M | 5.97M | 958K | 3.44M | (182.03M) |
| Total Non-current Liabilities | 232.53M | 246.47M | 237.98M | 222.17M | 194.31M |
| Total Liabilities | 352.42M | 367.58M | 346.77M | 309.95M | 343.43M |
| Common Stock | 2.39M | 2.44M | 2.5M | 2.7M | 3.09M |
| Retained Earnings | (195.92M) | (846.09M) | (999.7M) | (1.37B) | (1.95B) |
| Accumulated OCI | (5.07M) | (15.65M) | 1.91M | 1.84M | 4.82M |
| Other Stockholders Equity | 0 | 0 | 1 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 2.4B | 1.88B | 1.88B | 1.93B | 1.92B |
| Total Debt | 225.03M | 244.02M | 238.63M | 223.69M | 394.91M |
| Net Debt | (698M) | 32.14M | (150.85M) | (74.56M) | 39.73M |
CRISPR Therapeutics AG
NASDAQ:CRSP
Intrinsic Alpha fair value
Locked
Current Price
$40.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.